Cargando…

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via Newborn Screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction

PURPOSE: To assess the magnitude of benefit to early treatment initiation, enabled by newborn screening or prenatal diagnosis, in patients with cross-reactive immunological material (CRIM)-negative infantile Pompe disease (IPD), treated with enzyme replacement therapy (ERT) and prophylactic immune t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Cindy, Desai, Ankit K., Gupta, Punita, Dempsey, Katherine, Bhambhani, Vikas, Hopkin, Robert J., Ficicioglu, Can, Tanpaiboon, Pranoot, Craigen, William J., Rosenberg, Amy S., Kishnani, Priya S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107133/ https://www.ncbi.nlm.nih.gov/pubmed/33495531 http://dx.doi.org/10.1038/s41436-020-01080-y

Ejemplares similares

A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease
por: Gupta, Punita, et al.
Publicado: (2020)

Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy
por: Desai, Ankit K., et al.
Publicado: (2019)

Clinical laboratory experience of blood CRIM testing in infantile Pompe disease
por: Bali, Deeksha S., et al.
Publicado: (2015)

A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation
por: Curelaru, Shiri, et al.
Publicado: (2022)

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
por: Desai, Ankit K., et al.
Publicado: (2020)

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
por: van Gelder, Carin M., et al.
Publicado: (2014)

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
por: Kazi, Zoheb B., et al.
Publicado: (2018)

Long term outcome and clinical experience on immune tolerance induction therapies in infantile Pompe disease
por: Austin, Stephanie, et al.
Publicado: (2013)

Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant Cohort
por: Duong, Tina, et al.
Publicado: (2022)

Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease
por: Jones, Harrison N., et al.
Publicado: (2020)

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
por: Prater, Sean N, et al.
Publicado: (2013)

Newborn Screening for Pompe Disease: Pennsylvania Experience
por: Ficicioglu, Can, et al.
Publicado: (2020)

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
por: De Groot, Anne S., et al.
Publicado: (2021)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers
por: Stenger, Elizabeth O., et al.
Publicado: (2015)

Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease
por: Kishnani, Priya S., et al.
Publicado: (2019)

Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy
por: Kim, Katherine H., et al.
Publicado: (2023)

The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
por: Chiang, Shu-Chuan, et al.
Publicado: (2020)

Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016)

Un crim : i altres contes /
por: Calders, Pere, 1912-
Publicado: (1995)

Muscle ultrasound: A useful tool in newborn screening for infantile onset pompe disease
por: Hwang, Hsuen-En, et al.
Publicado: (2017)

Pompe disease- experience from South India
por: Lingappa, Lokesh, et al.
Publicado: (2013)

Behavioral, social and school functioning in children with Pompe disease
por: Korlimarla, Aditi, et al.
Publicado: (2020)

S2.2 Enzyme replacement therapy in the infantile-onset Pompe disease
por: Parenti, Giancarlo, et al.
Publicado: (2011)

Newborn Screening for Pompe Disease
por: Sawada, Takaaki, et al.
Publicado: (2020)

Development of a clinically validated in vitro functional assay to assess pathogenicity of novel GAA variants in patients with Pompe disease identified via newborn screening
por: Goomber, Shelly, et al.
Publicado: (2022)

Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease
por: Kwon, Jennifer M., et al.
Publicado: (2018)

Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease()
por: Chien, Yin-Hsiu, et al.
Publicado: (2017)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023)

New tools and approaches to newborn screening: ready to open Pandora's box?
por: Ficicioglu, Can
Publicado: (2017)

Development of Newborn Screening for Pompe Disease
por: Hwu, Wuh-Liang, et al.
Publicado: (2020)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

Crim1 suppresses left ventricular hypertrophy
por: Yang, Long, et al.
Publicado: (2019)

The Outcome of Infantile Onset Pompe Disease in South of Iran
por: Moravej, Hossein, et al.
Publicado: (2016)

The infantile-onset form of Pompe disease: an autopsy diagnosis
por: dos Santos, Otávio César Cruz, et al.
Publicado: (2015)

Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy
por: Quan, Jun-Jun, et al.
Publicado: (2017)

Nystagmus in infantile Pompe disease: a new feature?
por: Turco, Emanuela Claudia, et al.
Publicado: (2020)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
por: Banugaria, Suhrad G., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p45c5s59e3j74lvailkv3fe0sh